DK3589655T3 - Tandem diabody til cd16a målrettet nk-celle optagelse - Google Patents
Tandem diabody til cd16a målrettet nk-celle optagelse Download PDFInfo
- Publication number
- DK3589655T3 DK3589655T3 DK18708967.7T DK18708967T DK3589655T3 DK 3589655 T3 DK3589655 T3 DK 3589655T3 DK 18708967 T DK18708967 T DK 18708967T DK 3589655 T3 DK3589655 T3 DK 3589655T3
- Authority
- DK
- Denmark
- Prior art keywords
- cd16a
- targeted
- cell capture
- tandem diabody
- diabody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17158566 | 2017-02-28 | ||
| EP17174407 | 2017-06-02 | ||
| PCT/EP2018/054989 WO2018158349A1 (en) | 2017-02-28 | 2018-02-28 | Tandem diabody for cd16a-directed nk-cell engagement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3589655T3 true DK3589655T3 (da) | 2022-11-28 |
Family
ID=61569251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18708967.7T DK3589655T3 (da) | 2017-02-28 | 2018-02-28 | Tandem diabody til cd16a målrettet nk-celle optagelse |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11180558B2 (da) |
| EP (1) | EP3589655B1 (da) |
| JP (1) | JP7115758B2 (da) |
| CN (1) | CN110382539B (da) |
| AU (1) | AU2018228719B2 (da) |
| CA (1) | CA3051062C (da) |
| DK (1) | DK3589655T3 (da) |
| WO (1) | WO2018158349A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52227A (fr) | 2018-04-13 | 2021-04-21 | Affimed Gmbh | Constructions de fusion d'anticorps entrant en contact avec des cellules nk |
| EP4286410A1 (en) * | 2021-01-27 | 2023-12-06 | Innovent Biologics (Suzhou) Co., Ltd. | Single-domain antibody against cd16a and use thereof |
| CA3233696A1 (en) * | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
| AU2022381918A1 (en) * | 2021-11-03 | 2024-06-13 | Affimed Gmbh | Bispecific cd16a binders |
| CN114262382B (zh) * | 2021-12-20 | 2023-09-19 | 上海恩凯细胞技术有限公司 | 双特异性抗体及其应用 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN115960234B (zh) * | 2022-10-27 | 2023-12-29 | 合肥天港免疫药物有限公司 | 抗cd16a的抗体及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| JP2004533997A (ja) | 2001-02-20 | 2004-11-11 | ザイモジェネティクス，インコーポレイティド | Ｂｃｍａ及びｔａｃｉの両者を結合する抗体 |
| ATE356149T1 (de) * | 2001-11-14 | 2007-03-15 | Affimed Therapeutics Ag | Bispezifische antikörper gegen cd19 und cd16 und deren verwendung |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| PL2158221T3 (pl) * | 2007-06-21 | 2019-02-28 | Macrogenics, Inc. | Kowalencyjne diaciała i ich zastosowania |
| CN102421801B (zh) | 2009-03-10 | 2016-03-16 | 比奥根Ma公司 | 抗-bcma抗体 |
| US20110206672A1 (en) * | 2010-02-25 | 2011-08-25 | Melvyn Little | Antigen-Binding Molecule And Uses Thereof |
| LT2361936T (lt) * | 2010-02-25 | 2016-09-12 | Affimed Gmbh | Antigeną rišanti molekulė ir jos panaudojimas |
| JP6263467B2 (ja) | 2011-05-27 | 2018-01-17 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）結合タンパク質 |
| BR112014001573B8 (pt) | 2011-07-22 | 2022-11-08 | Affimed Therapeutics Ag | Molécula fv ao antígeno multivalente |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| US10189906B2 (en) | 2012-11-01 | 2019-01-29 | Max-Delrück-Centrum Für Molekulare Medizin | Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| EP2953974B1 (en) | 2013-02-05 | 2017-12-20 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and bcma |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
| RU2696892C2 (ru) | 2013-08-07 | 2019-08-07 | Аффимед Гмбх | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| EP3292153B1 (en) * | 2015-05-04 | 2019-07-31 | Affimed GmbH | Combination of a cd30xcd16a antibody with an anti-pd-1 antagonistic antibody for therapy |
| CN105367660B (zh) * | 2015-12-22 | 2018-12-21 | 深圳市北科生物科技有限公司 | 一种抗cd16a抗原和抗muc1抗原的双特异性抗体 |
-
2018
- 2018-02-28 CN CN201880014655.0A patent/CN110382539B/zh active Active
- 2018-02-28 AU AU2018228719A patent/AU2018228719B2/en active Active
- 2018-02-28 CA CA3051062A patent/CA3051062C/en active Active
- 2018-02-28 JP JP2019546903A patent/JP7115758B2/ja active Active
- 2018-02-28 DK DK18708967.7T patent/DK3589655T3/da active
- 2018-02-28 WO PCT/EP2018/054989 patent/WO2018158349A1/en unknown
- 2018-02-28 EP EP18708967.7A patent/EP3589655B1/en active Active
-
2019
- 2019-07-23 US US16/520,218 patent/US11180558B2/en active Active
-
2021
- 2021-10-26 US US17/510,738 patent/US20220041717A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11180558B2 (en) | 2021-11-23 |
| EP3589655B1 (en) | 2022-10-26 |
| US20190345249A1 (en) | 2019-11-14 |
| JP2020510659A (ja) | 2020-04-09 |
| CA3051062A1 (en) | 2018-09-07 |
| AU2018228719B2 (en) | 2023-03-30 |
| CN110382539B (zh) | 2023-08-08 |
| JP7115758B2 (ja) | 2022-08-09 |
| AU2018228719A1 (en) | 2019-08-08 |
| WO2018158349A1 (en) | 2018-09-07 |
| EP3589655A1 (en) | 2020-01-08 |
| CA3051062C (en) | 2023-09-26 |
| CN110382539A (zh) | 2019-10-25 |
| US20220041717A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3589655T3 (da) | Tandem diabody til cd16a målrettet nk-celle optagelse | |
| CL2018000281A1 (es) | Anticuerpos monoclonales contra bcma | |
| DK3177484T3 (da) | Forbedret kommunikationssystem til køretøjskatastrofeblink | |
| DK3368101T3 (da) | Autoinjektor til engangsbrug | |
| DK3215601T3 (da) | Fremgangsmåder til transduktion og celleforarbejdning | |
| DK3212789T3 (da) | Massiv parallel kombinatorisk genetik til crispr | |
| DK3316703T3 (da) | Fremgangsmåde til forbedring af dyrs ydeevne | |
| DK3213065T3 (da) | System og fremgangsmåder til todimensionel rplc-sfc-kromatografi | |
| DK3352625T3 (da) | Reorganiserbar liggestol til flere formål, flere anvendelser | |
| DK3313997T3 (da) | Fremgangsmåde til fremstilling af mølferomoner i gær | |
| DK3405580T3 (da) | Ekspressionssystem til eukaryotiske organismer | |
| DK3397294T3 (da) | Fremgangsmåde til fremstilling af 3d-bruskorganoidblok | |
| FR3028872B1 (fr) | Procede de fractionnement | |
| EP3172765A4 (en) | Through array routing for non-volatile memory | |
| ZA201603750B (en) | Method and system for assessing performance of arbitrarily large arrays | |
| DK3198284T3 (da) | Paletbaserede systemer til analytkarakterisering | |
| DK3009092T3 (da) | Effektiv parasitær kapacitetsminimering til mikroablationselektrode | |
| DK3596379T3 (da) | Fremstillingsfremgangsmåde til katodisk beskyttelse | |
| EP3728612C0 (en) | METHOD FOR TRANSDUCING NK CELLS | |
| FR3042832B1 (fr) | Ecrou etanche | |
| DK3640164T3 (da) | Justerbare transportørsystemer | |
| DK3512536T3 (da) | Pd-1-peptidinhibitorer | |
| IT201700117804A1 (it) | Unità di crimpatura | |
| FR3045219B1 (fr) | Cellule rayonnante elementaire multi-bande | |
| FR3023067B1 (fr) | Cellules tandem multifils |